By Michael Susin

GSK said a jury verdict in Illinois state ruled that the group is not liable for the plaintiff's colorectal cancer in a trial related to the company's heartburn drug Zantac.

The British pharmaceutical company on Thursday said the Valadez case is the first lawsuit related to Zantac to go to trial.

"This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer," the company said.

It added that the next trial, the Williams case, was dismissed by the Illinois court before trial because GSK wasn't the brand manufacturer of the over-the-counter drug at the time the accuser allegedly used it.

The company added that it will continue to defend itself in all other Zantac cases.

Write to Michael Susin at

(END) Dow Jones Newswires

05-24-24 0155ET